Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H22ClNO5 |
Molecular Weight | 391.845 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CC1=CC=C2O[C@H](COC2=C1)C(O)=O)NC[C@H](O)C3=CC=CC(Cl)=C3
InChI
InChIKey=XSOXUIXLUNBLJA-RNRVQEDPSA-N
InChI=1S/C20H22ClNO5/c1-12(22-10-16(23)14-3-2-4-15(21)9-14)7-13-5-6-17-18(8-13)26-11-19(27-17)20(24)25/h2-6,8-9,12,16,19,22-23H,7,10-11H2,1H3,(H,24,25)/t12-,16+,19-/m1/s1
Molecular Formula | C20H22ClNO5 |
Molecular Weight | 391.845 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:23:05 GMT 2023
by
admin
on
Sat Dec 16 08:23:05 GMT 2023
|
Record UNII |
TV97A9Z8ZT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9865284
Created by
admin on Sat Dec 16 08:23:05 GMT 2023 , Edited by admin on Sat Dec 16 08:23:05 GMT 2023
|
PRIMARY | |||
|
TV97A9Z8ZT
Created by
admin on Sat Dec 16 08:23:05 GMT 2023 , Edited by admin on Sat Dec 16 08:23:05 GMT 2023
|
PRIMARY | |||
|
220475-76-3
Created by
admin on Sat Dec 16 08:23:05 GMT 2023 , Edited by admin on Sat Dec 16 08:23:05 GMT 2023
|
PRIMARY | |||
|
N-5984
Created by
admin on Sat Dec 16 08:23:05 GMT 2023 , Edited by admin on Sat Dec 16 08:23:05 GMT 2023
|
PRIMARY | Developer: Kyorin Pharmaceutical Nisshin Pharma; Class: Anti-hyperglycaemic, Carboxylic acid, Dioxin, Obesity therapy, Small molecule; Mechanism of Action: Beta 3 adrenergic receptor agonist;Highest Development Phase: Discontinued for Diabetes mellitus, Obesity, Overactive bladder |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Kyorin Pharmaceutical Co. Ltd.'s KRP-204, a selective ADRB3 agonist, is in Phase II testing to treat obesity and incontinence.
|
||
|
ACTIVE MOIETY |
Therefore, we examined whether KRP-204, a selective beta3-AR agonist (EC50=1.7 nM, in CHO cells expressing human beta3-AR), acts on C-fiber afferent nerves by observing the licking behavior induced by intravesical instillation of capsaicin in rats.
|